Patient Group Mentoring programme

Launched in 2018, the Patient Group Mentoring programme is a tailored mentorship programme dedicated to building capacity of a representative cohort of patient groups at the regional level.

people chatting together

The programme works with patient-driven organisations that face challenges in accessing opportunities, while having the minimum capacity to engage in the offered opportunities and clear potential for growth in their region and beyond.

The main objective of this programme is that patient groups are engaged and heard as a key partners in the cancer community and health systems, at the local, regional and global levels. Through tailored assistance to access capacity building opportunities and efforts to connect patient groups, UICC adapts its approach to the specific needs of patient groups in relevant regions.


  • Increase peer-to-peer support and collaborations between patient groups through dedicated activities and platforms
  • Maximise the representation of patients’ voices in the cancer community at the regional and global level
  • Ensure access to UICC capacity building opportunities and other membership benefits, through tailored assistance and development of dedicated activities.
  • Connect patient groups with key relevant initiatives at the regional and global levels, through a mapping of opportunities and connections with partners and stakeholders

How does the programme work? 

In each region:

  • Patient groups are invited to apply to join the programme. Selection criteria are based on needs, geographical and cancer type representation, level of development, potential for growth and minimum capacity to engage in capacity building opportunities (e.g. basic level in English is required).
  • All groups complete a needs assessment and have the opportunity to flag additional needs as they arise. On this basis, a mapping of regional and global opportunities (from UICC and from other stakeholders in the region) is defined and shared with the groups.
  • A virtual collaborative platform is made available for groups to share their activities and access resources. In some regions, additional social netwoking is also established, to increase interaction and to facilitate the exchange of information.
  • UICC coordinates regular virtual meetings (monthly) for all groups to share information, collaborate and showcase opportunities. A dedicated programme of collective activities is coordinated by UICC, such as webinars on specific topics deemed relevant (e.g. digital fundraising or advocacy).
  • When possible, UICC capitalises on convening activities (from UICC and other stakeholders) at the regional level to ensure that patient groups participate in these events and represent the voice of cancer patients in key regional cancer events.

Interested in joining the programme?


Benefits from the programme

Sponsored full membership

  1. Have a voice in regional and global cancer control fora, share the patient perspective by engaging as speakers, contributors or participants.
  2. Access a full range of adapted capacity building opportunities, including learning through Master courses, Virtual Dialogues and other activities
  3. Gain more confidence in engaging with other stakeholders in their own setting
  4. Share experience and knowledge with peers at the regional and global levels
  5. Access tailored assistance and materials for creating momentum on relevant dates, particularly through World Cancer Day
  6. Be part of convening opportunities such as the Virtual Dialogues, World Cancer Congress and World Cancer Leaders’ Summit
  7. Benefit from outreach about key opportunities from UICC, its members, partners and network (e.g. City Cancer Challenge, NCD Alliance)
  8. Be informed about key global commitments in cancer control (e.g. Global Strategy on cervical cancer elimination or the Cancer Resolution)
  9. Be connected with a network of 1,200 cancer organisations worldwide

Upcoming Virtual dialogue on PGMP

The programme in the regions

The programme is currently being deployed in two regions, Asia Pacific and Eastern Mediterranean. To learn more about the programme in these regions, we encourage you to visit the dedicated pages: 

Launched in 2018 as a pilot initiative to respond to a voiced need in the Asia Pacific (APAC) region, the programme aims to ensure that patient groups have the knowledge, capacity and connections to make a difference in their own health systems and beyond.

This regional programme is part of the broader Patient Group Mentoring Programme.

This regional programme is part of the broader Patient Group Mentoring Programme.

The Patient Groups Mentoring programme is kindly supported in 2023 by Amgen, Bristol Myers Squibb (BMS) and MSD.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Participants of a workshop at the 2022 World Cancer Congress in Geneva, Switzerland (October 2022)

Fostering an influential cancer community with the skills, knowledge, networks and resources to achieve effective cancer prevention and control.  

Man looking at video on his computer

UICC has been supporting the continuing education of cancer control professionals through online learning since 2014.

A male nurse checks a screen during a surgery

UICC has a long history of building capacity for cancer organisations globally through grant making.

Two doctors consult a document in the hallways of an hospital in Mexico

Established in 1962, the Fellowships is one of UICC's oldest and most established portfolio of programmes.

Woman smiling

The UICC's organisational leadership workstream is designed to provide leaders in cancer organisations at all levels with spaces to acquire new skills, and opportunities to collaborate and take action together.

Participants of the Cancer Advocacy Programme showing their coloured hands

UICC’s Cancer Advocates programme provides an opportunity for civil society organisations (CSOs) from low- and middle-income countries to gain the skills and knowledge to engage in national advocacy efforts for improved cancer control. The programme is available in English, French and Spanish.

UICC's Virtual Dialogues provide members, and the cancer community, with regular opportunities to connect, exchange knowledge, access expert insights, and share solutions from the comfort of one's office or home.

Last update

Thursday 20 June 2024

Share this page